DK3242890T3 - Agonistiske tnf-receptor-bindingsmidler - Google Patents

Agonistiske tnf-receptor-bindingsmidler Download PDF

Info

Publication number
DK3242890T3
DK3242890T3 DK16700136.1T DK16700136T DK3242890T3 DK 3242890 T3 DK3242890 T3 DK 3242890T3 DK 16700136 T DK16700136 T DK 16700136T DK 3242890 T3 DK3242890 T3 DK 3242890T3
Authority
DK
Denmark
Prior art keywords
receptor binding
binding agents
tnf receptor
agonistic
agonistic tnf
Prior art date
Application number
DK16700136.1T
Other languages
English (en)
Inventor
Ugur Sahin
Friederike Gieseke
Isil Altintas
David Satijn
Paul Parren
Original Assignee
BioNTech SE
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioNTech SE, Genmab As filed Critical BioNTech SE
Application granted granted Critical
Publication of DK3242890T3 publication Critical patent/DK3242890T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
DK16700136.1T 2015-01-08 2016-01-08 Agonistiske tnf-receptor-bindingsmidler DK3242890T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2015050255 2015-01-08
PCT/EP2016/050308 WO2016110584A1 (en) 2015-01-08 2016-01-08 Agonistic tnf receptor binding agents

Publications (1)

Publication Number Publication Date
DK3242890T3 true DK3242890T3 (da) 2019-10-21

Family

ID=55072677

Family Applications (2)

Application Number Title Priority Date Filing Date
DK16700136.1T DK3242890T3 (da) 2015-01-08 2016-01-08 Agonistiske tnf-receptor-bindingsmidler
DK19194817.3T DK3623386T3 (da) 2015-01-08 2016-01-08 Agonistiske tnf-receptor-bindingsmidler

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK19194817.3T DK3623386T3 (da) 2015-01-08 2016-01-08 Agonistiske tnf-receptor-bindingsmidler

Country Status (24)

Country Link
US (3) US10457735B2 (da)
EP (3) EP3242890B1 (da)
JP (4) JP6744326B2 (da)
KR (3) KR102238326B1 (da)
CN (3) CN111499752B (da)
AU (2) AU2016205974B2 (da)
BR (1) BR112017013189B1 (da)
CA (2) CA3224830A1 (da)
CY (1) CY1122399T1 (da)
DK (2) DK3242890T3 (da)
ES (2) ES2922398T3 (da)
HR (2) HRP20220811T1 (da)
HU (2) HUE059219T2 (da)
LT (1) LT3623386T (da)
ME (1) ME03576B (da)
MX (2) MX2017008917A (da)
PL (2) PL3242890T3 (da)
PT (2) PT3242890T (da)
RS (2) RS63384B1 (da)
RU (1) RU2723131C2 (da)
SG (2) SG11201704597WA (da)
SI (2) SI3623386T1 (da)
WO (1) WO2016110584A1 (da)
ZA (1) ZA201704797B (da)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014110601A1 (en) 2013-01-14 2014-07-17 Xencor, Inc. Novel heterodimeric proteins
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
ME03666B (me) 2014-03-28 2020-10-20 Xencor Inc Bispecifična antitela koja se vezuju za cd38 i cd3
EP3223907A2 (en) 2014-11-26 2017-10-04 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
KR20170084326A (ko) 2014-11-26 2017-07-19 젠코어 인코포레이티드 Ｃｄ3 및 종양 항원과 결합하는 이종이량체 항체
US10259882B2 (en) 2015-05-07 2019-04-16 Agenus Inc. Anti-OX40 antibodies
US11447557B2 (en) 2015-12-02 2022-09-20 Agenus Inc. Antibodies and methods of use thereof
CN108699136B (zh) 2015-12-07 2022-03-18 Xencor股份有限公司 结合cd3和psma的异二聚抗体
PE20181535A1 (es) 2015-12-16 2018-09-26 Gritstone Oncology Inc Identificacion, fabricacion y uso de neoantigeno
JP2019523630A (ja) * 2016-04-22 2019-08-29 アリゲーター・バイオサイエンス・アーベー Ｃｄ１３７に対する新規の二重特異性ポリペプチド
EP4257613A3 (en) 2016-06-14 2023-12-13 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
EP3475304B1 (en) 2016-06-28 2022-03-23 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
CA3030636A1 (en) * 2016-07-14 2018-01-18 Genmab A/S Multispecific antibodies against cd40 and cd137
WO2018045110A1 (en) * 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
EP3507306A1 (en) * 2016-08-30 2019-07-10 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
WO2018056821A1 (en) * 2016-09-23 2018-03-29 Merus N.V. Binding molecules that modulate a biological activity expressed by a cell
CA3041340A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
WO2018134787A2 (en) 2017-01-20 2018-07-26 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd137+ cells
JP2020511959A (ja) * 2017-03-29 2020-04-23 グリコトープ ゲーエムベーハー ヒト化抗ｃｄ４０抗体
CA3070272A1 (en) 2017-07-20 2019-01-24 Aptevo Research And Development Llc Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
KR20200064062A (ko) 2017-08-04 2020-06-05 젠맵 에이/에스 Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
EP3676294A4 (en) * 2017-08-28 2021-12-22 Systimmune, Inc. ANTI-CD3 ANTIBODIES AND METHOD OF MANUFACTURING AND USING THEREOF
JP7227237B2 (ja) 2017-10-10 2023-02-21 グリットストーン バイオ インコーポレイテッド ホットスポットを利用した新生抗原の特定
JP2021502100A (ja) 2017-11-08 2021-01-28 ゼンコア インコーポレイテッド 新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
AU2018373154A1 (en) 2017-11-22 2020-07-02 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
AU2018390418B2 (en) 2017-12-19 2023-12-21 Xencor, Inc. Engineered IL-2 Fc fusion proteins
EP3773911A2 (en) 2018-04-04 2021-02-17 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
AU2019256539A1 (en) 2018-04-18 2020-11-26 Xencor, Inc. PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
EP3781598A1 (en) 2018-04-18 2021-02-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
US11845797B2 (en) 2018-07-03 2023-12-19 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
AU2019355971A1 (en) 2018-10-03 2021-05-06 Xencor, Inc. IL-12 heterodimeric Fc-fusion proteins
CA3118789A1 (en) 2018-11-06 2020-05-14 Genmab A/S Antibody formulation
JP7463366B2 (ja) 2018-11-20 2024-04-08 タケダ ワクチン，インコーポレイテッド 新規の抗ジカウイルス抗体及びその使用
CA3132185A1 (en) 2019-03-01 2020-09-10 Xencor, Inc. Heterodimeric antibodies that bind enpp3 and cd3
SG11202110287QA (en) 2019-04-24 2021-10-28 Heidelberg Pharma Res Gmbh Amatoxin antibody-drug conjugates and uses thereof
BR112022015151A2 (pt) 2020-02-04 2022-12-20 Genmab As Método para reduzir ou prevenir progressão de um tumor ou tratar câncer, e, composição
US11940448B2 (en) 2020-03-31 2024-03-26 Seattle Children's Hospital Proteomic screening for lysosomal storage diseases
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
KR102607909B1 (ko) 2020-08-19 2023-12-01 젠코어 인코포레이티드 항-cd28 조성물
CN112175080B (zh) * 2020-10-22 2021-05-25 优睿赛思(武汉)生物科技有限公司 抗人白介素-6高亲和力兔单克隆抗体及应用
KR20230128482A (ko) 2020-12-07 2023-09-05 젠맵 에이/에스 항체와 탁산의 조합 요법
IL305736A (en) 2021-03-09 2023-11-01 Xencor Inc Heterodimeric antibodies that bind CD3 and CLDN6
CA3211334A1 (en) * 2021-03-09 2022-09-15 Yali FU Multispecific binding agents against cd40 and cd137 in therapy
EP4305065A1 (en) 2021-03-10 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3
BR112023020832A2 (pt) 2021-04-08 2023-12-19 Marengo Therapeutics Inc Moléculas multifuncionais ligadas a tcr e seus usos
TW202315891A (zh) 2021-06-21 2023-04-16 丹麥商珍美寶股份有限公司 結合劑給藥排程
WO2024050318A1 (en) * 2022-08-27 2024-03-07 H. Lee Moffitt Cancer Center And Research Institute Cd40l 41bbl bispecific proteins

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
EP1482972A4 (en) * 2001-11-20 2005-11-23 Seattle Genetics Inc TREATMENT OF IMMUNOLOGICAL DISORDERS USING ANTI-CD30 ANTIBODIES
CN101023102B (zh) * 2004-09-17 2013-05-29 霍夫曼-拉罗奇有限公司 抗-ox40l抗体
NZ591252A (en) * 2006-03-17 2012-06-29 Biogen Idec Inc Methods of designing antibody or antigen binding fragments thereof with substituted non-covarying amino acids
GB0620894D0 (en) * 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
US20100136030A1 (en) 2007-02-27 2010-06-03 Lamhamedi-Cherradi Salah-Eddine Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
ES2667863T3 (es) 2007-03-29 2018-05-14 Genmab A/S Anticuerpos biespecíficos y métodos de producción de los mismos
PL2201100T3 (pl) 2007-09-14 2016-10-31 Wzmacnianie zdolności ludzkich komórek prezentujących antygen do stymulacji komórek T i ich zastosowanie w szczepieniu
EP2851374B1 (en) * 2007-12-14 2017-05-03 Bristol-Myers Squibb Company Binding molecules to the human OX40 receptor
US9931386B2 (en) * 2008-06-16 2018-04-03 Atsuo Ochi Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
JP5782385B2 (ja) 2009-02-17 2015-09-24 ユーシービー ファーマ ソシエテ アノニム ヒトｏｘ４０に対する特異性を有する抗体分子
AU2011275749C1 (en) 2010-07-09 2015-09-17 Aduro Biotech Holdings, Europe B.V. Agonistic antibody to CD27
PT2663580T (pt) 2011-01-10 2017-03-10 Univ Zuerich Terapêutica de associação incluindo anticorpos de ligação a antigénios associados a tumores
EA036047B1 (ru) 2011-07-11 2020-09-18 Икнос Сайенсиз Са Антитела, которые связываются с ox40, и их применение
CN103946238B (zh) * 2011-08-23 2016-10-12 德克萨斯州立大学董事会 抗ox40抗体及使用其的方法
GB201116092D0 (en) * 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
PT2976361T (pt) * 2013-03-18 2018-10-19 Janssen Pharmaceuticals Inc Anticorpos anti-cd134 (ox40) humanizados e utilizações dos mesmos
CA3030636A1 (en) * 2016-07-14 2018-01-18 Genmab A/S Multispecific antibodies against cd40 and cd137

Also Published As

Publication number Publication date
RS63384B1 (sr) 2022-08-31
SI3623386T1 (sl) 2022-09-30
AU2016205974B2 (en) 2021-11-04
US10927181B2 (en) 2021-02-23
US20180194849A1 (en) 2018-07-12
NZ733157A (en) 2021-10-29
US10457735B2 (en) 2019-10-29
EP3242890A1 (en) 2017-11-15
JP6950056B2 (ja) 2021-10-13
CN109476761A (zh) 2019-03-15
KR102640769B1 (ko) 2024-02-27
JP2023085435A (ja) 2023-06-20
KR102238326B1 (ko) 2021-04-12
JP2020188797A (ja) 2020-11-26
HRP20191824T1 (hr) 2020-01-24
US11814411B2 (en) 2023-11-14
MX2017008917A (es) 2018-02-09
JP7487376B2 (ja) 2024-05-20
DK3623386T3 (da) 2022-07-04
ES2755527T3 (es) 2020-04-22
BR112017013189B1 (pt) 2024-03-05
RU2017127792A3 (da) 2019-06-17
RU2723131C2 (ru) 2020-06-08
EP3623386B1 (en) 2022-04-13
CN111499752B (zh) 2024-05-31
CN109476761B (zh) 2020-01-10
EP3623386A1 (en) 2020-03-18
KR20240028548A (ko) 2024-03-05
PT3242890T (pt) 2019-12-10
HUE048532T2 (hu) 2020-07-28
CY1122399T1 (el) 2020-11-25
PL3242890T3 (pl) 2020-04-30
MX2020012240A (es) 2021-02-22
RS59693B1 (sr) 2020-01-31
KR20170132717A (ko) 2017-12-04
SI3242890T1 (sl) 2020-01-31
CN117843799A (zh) 2024-04-09
AU2016205974A1 (en) 2017-07-13
JP6744326B2 (ja) 2020-08-19
ME03576B (me) 2020-07-20
EP4071176A2 (en) 2022-10-12
CA2969888A1 (en) 2016-07-14
CN111499752A (zh) 2020-08-07
SG11201704597WA (en) 2017-07-28
PT3623386T (pt) 2022-07-18
JP2022025064A (ja) 2022-02-09
LT3623386T (lt) 2022-08-10
BR112017013189A2 (pt) 2018-04-10
RU2017127792A (ru) 2019-02-08
ES2922398T3 (es) 2022-09-14
JP2018506298A (ja) 2018-03-08
AU2022200571A1 (en) 2022-02-17
CA3224830A1 (en) 2016-07-14
US20200079866A1 (en) 2020-03-12
HRP20220811T1 (hr) 2022-09-30
JP7390345B2 (ja) 2023-12-01
PL3623386T3 (pl) 2022-08-08
SG10202003171TA (en) 2020-05-28
HUE059219T2 (hu) 2022-10-28
EP4071176A3 (en) 2022-12-14
ZA201704797B (en) 2019-05-29
WO2016110584A1 (en) 2016-07-14
US20210253725A1 (en) 2021-08-19
RU2020115901A (ru) 2020-08-05
KR20210041634A (ko) 2021-04-15
EP3242890B1 (en) 2019-09-04

Similar Documents

Publication Publication Date Title
DK3242890T3 (da) Agonistiske tnf-receptor-bindingsmidler
ZA201802371B (en) Glucagon receptor agonists
MA43382A (fr) Modulateurs des récepteurs des chimiokines
DK3294764T3 (da) Kimæriske antigenreceptor sammensætninger
GB201514875D0 (en) Receptor
HK1252163A1 (zh) 受體
DK3283110T3 (da) Antistoffer rettet mod interleukin-36-receptor (il-36r)
DK3300500T3 (da) Triazolagonister af apj-receptoren
DK3242892T3 (da) Modificerede april-bindende antistoffer
MA41653A (fr) Liants de tnf améliorés
ZA201706673B (en) Modified bituminous binder emulsion
DK3212637T3 (da) Dopamin-d3-receptorantagonistforbindelser
DK3334721T3 (da) Cgrp-receptorantagonister
DE102016013104A8 (de) Skibindung
IL272798A (en) TNF receptor binding agonists
HUE047148T2 (hu) MET receptor antagonista proteinek
TH1601000316A (th) อะโกนิสต์ของตัวรับวาโซเพรสซิน-2